Christopher B. Granger, MD

Related Content

Services

• Emergency Services
• General and Consultative Heart Care

Department / Division:
Medicine / Cardiovascular Medicine

Address:
DUMC 3409
Durham, NC 27710

Appointment Telephone:
919-681-5816

Office Telephone:
919-668-8900

Fax Telephone:
919-668-7056

• MD, University of Connecticut School of Medicine, 1984

• Internal Medicine, University of Colorado, 1984-1989
• Cardiology, Duke University Medical Center, 1989-1992

Clinical Interests:
Critical care and general cardiology, acute myocardial infarction, unstable angina, congestive heart failure, valvular heart disease

Research Interests:

My primary research interest is in conduct and methodology of large randomized clinical trials in heart disease.  My major activity from 1993 to the present has been in trials involving acute ischemic heart disease, including coordination of the Global Utilization of Streptokinase and t-PA for Occluded Coronary Arteries (GUSTO) Trial, the GUSTO II trials, co-PI on the GUSTO III trial, the AMISTAD trial which is investigating the use of adenosine to prevent reperfusion injury with thrombolytic therapy for acute myocardial infarction, and the SPICE Trial which is investigating the use of Candesartin in patients with ACE inhibitor intolerance and heart failure.  Methodological issues of interest have included developing better classification systems for clinical events in large clinical trials, developing international networks and comprehensive databases of clinical investigator sites, and studying the impact and cost-effectiveness of data auditing.  Other areas of interest have included optimizing the level of anticoagulation following acute myocardial infarction and unstable angina, understanding the occurrence and optimal management of stoke following thrombolytic therapy, development of new treatments for heart failure, understanding mechanisms of anticoagulation and the phenomenon of reactivation of thrombosis upon discontinuation of anticoagulants, and identification of genetic markers of atherosclerosis.  

Key words:  thrombolytic therapy, anticoagulation, antithrombin, unstable angina.

Representative Publications:
Granger CB, Becker R, Tracy RP, Califf RM, Topol EJ, Pieper K, Ross A, Roth S, Lambrew C, Bovill EG, for the GUSTO hemostasis substudy group. Thrombin generation, inhibition and clinical outcomes in patients with acute myocardial infarction treated with thrombolytic therapy and heparin: results from the GUSTO trial. J Am Coll Cardiol (in press, 1997). (1997)

Granger CB, Hirsh J, Califf RM, Col J, White HD, Betriu A, Woodlief LH, Lee KL, Bovill E, Simes RJ, Topol EJ, for the GUSTO Trial Investigators. Activated partial thromboplastin time and outcome after thrombolytic therapy for acute myocardial infarction: results from the GUSTO Trial. Circulation 1996;93:870-88. (1996)

Granger CB, Miller JM, Bovill EG, Gruber A, Tracy RP, Berrios E, Green C, Krucoff M, Harrington RA, Ohman EM, Califf RM. Rebound increase in thrombin generation and activity after cessation of intravenous heparin in patients with acute coronary syndromes. Circulation 1995;91:1929-35. (1995)

Granger CB, White H, Bates E, Ohman EM, Califf RM. A pooled analysis of coronary arterial patency and left ventricular function after intravenous thrombolysis for acute myocardial infarction. Am J Cardiol 1994;74:1220-28. (1994)

Granger CB, Califf RM, Young S, Candela R, Samaha J, Worley S, Kereiakes DJ, Topol EJ, and the TAMI Study Group. Outcomes of patients with diabetes mellitus and acute myocardial infarction treated with thrombolytic therapy. J Am Coll Cardiol 1993;21:920-925. (1993)